SCHOTT Pharma focuses on possible fill-and-finish solutions based on increased usage of pre-washed and pre-sterilised drug containers compared with traditional filling concepts that work with purchasing non-sterile, so-called ‘bulk’ containers from primary packaging suppliers.
Schott logo
Key insights:
- The challenges affecting drug manufacturing and filling operations are reducing value chain complexity, detecting and eliminating areas breaching patient safety, andspeeding up time to market to maximise patent lifetimes.
- For fill-and-finish operations, the total costs of ownership (TCO) can be calculated for RTU containers in different scenarios to help pharma companies choose the right packaging configuration for their business case.
- Switching from bulk to RTU containers can significantly speed up the time to market for new products thanks to the reduction in qualification and validation resources required.
Pharmaceutical companies are continuously assessing the productiveness of their filling lines to achieve higher yields with fewer resources thereby ensuring high quality standards and maintaining flexibility in the fill-and-finish process. Lower cost, better quality and higher flexibility might appear to be contradictory goals.